Nokia Corporation (ADR) (NYSE:NOK) ended lower by -0.17 points or -4.16% t

Generex Biotechnology Corporation (OTC:GNBT) ended higher by 0.0238 points or 59.50% to complete the day at 0.0638

DryShips Inc. (NASDAQ:DRYS) ended lower by -0.13 points or -5.70% to complete the day at 2.15. The total number of shares changed hands during the day was 5.33 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) ended higher by 0.13 points or 1.56% to complete the day at 8.49

Meru Networks, Inc. (NASDAQ:MERU) ended higher by 1.00 points or 41.67% to complete the day at 3.40.

Velti Plc (NASDAQ:VELT) ended lower by -1.38 points or -25.23% to complete the day at 4.09

Barrick Gold Corporation (USA) (NYSE:ABX) declined -1.34% with the closing price of $32.39

Apple Inc. (NASDAQ:AAPL) declared the addition of a higher capacity iPad 4 with Retina display to its product family

Research In Motion Limited (USA) (NASDAQ:RIMM) launched its latest Blackberry 10 based on the most recent operating System

OCZ Technology Group Inc. (NASDAQ:OCZ) ended lower by -0.39 points or -14.55% to complete the day at 2.29

Boston Scientific Corporation (NYSE:BSX) ended higher by 0.24 points or 3.50% to complete the day at 7.10

Amazon.com, Inc. (NASDAQ:AMZN) shares declined after it reported its quarterly results and the Internet retail giant's sales

Apple Inc. (NASDAQ:AAPL) will start an R&D and procurement management capability in the city this summer. Apple has been dispatched for statement.

GOLDEN SPIRIT ENTERPS LTD (OTC:GSPT) ended higher by 0.0134 points or 837.50% to complete the day at 0.0150

Keryx Biopharmaceuticals (NASDAQ:KERX) ended higher by 2.30 points or 38.01% to complete the day at 8.36

Amgen, Inc. (NASDAQ:AMGN) ended higher by 1.00 points or 1.17% to complete the day at 86.59

Canterbury Res Inc (OTC:ECAU) ended higher by 0.76 points or 45.78% to complete the day at 2.42.

Microsoft Corporation (NASDAQ:MSFT) reported its superlative quarter in history in terms of revenue

Keryx Biopharmaceuticals (NASDAQ:KERX) shares moved up after the drug developer reported its phase 3 results for chronic latent kidney disease drug, Zerenex, accomplished much better than a placebo in a late-stage clinical trial

Yahoo! Inc. (NASDAQ:YHOO) reported fourth-quarter results that surpassed analysts’ estimations and augmented annual sales for the first time since 2008 as the biggest U.S. Web gateway promoted from floating demand for online search.